The startup using AI to help rare disease families develop custom treatments
The world of rare disease treatment is a complex and often frustrating landscape for patients and their families. It's a realm where diagnosis can be elusive, treatment options scarce, and hope often hangs by a thread. But amidst this challenge, a new player has emerged, leveraging the power of artificial intelligence to offer a glimmer of light to those in the darkest of times.
This player is Nome, a startup founded by Stevie Ringel, who himself has a personal connection to the rare disease world. Ringel's journey began when he and his sister were diagnosed with a rare retinal dystrophy caused by a mutation of the KIZ gene. With no FDA-approved treatment options available, Ringel launched the Kizuna Foundation to raise funds for individualized treatment. This experience fueled his determination to create a solution for others facing similar struggles.
Nome's mission is to provide a "white glove service" for developing treatments for underserved patient populations. It offers a comprehensive approach, starting with a genetic test that identifies a genetic disorder. Nome's AI platform then analyzes the test results, searching for potential treatment options. This process is remarkably efficient, with the AI system providing insights in just 10 minutes, thanks to the expertise of a PhD in the loop.
The startup's AI models are designed to help design clinical trials and manage the logistics of these complex operations. Ringel believes that AI will play a pivotal role in making personalized medicine more accessible and cost-effective. He estimates that a customized ASO can cost between $1.2 and $1.4 million, and by reducing this cost by 50%, they hope to create a pathway where insurance might even start to cover these treatments.
Nome's impact is already being felt by groups like The DAND Alliance, which was founded by Jacalyn Lee after her daughter, Isla, was diagnosed with DEAF1-Associated Neurodevelopmental Disorder (DAND). DAND is an ultra-rare genetic condition with limited research and support. Lee's efforts to gather information and connect with researchers led her to Nome, where they provided a 53-page report detailing next steps and outlining various aspects of the treatment development process.
The startup's ability to provide a detailed roadmap and guidance within a tight timeframe and at a reasonable price point was a game-changer for The DAND Alliance. Lee's experience highlights the immense value that Nome brings to rare disease communities, offering a sense of direction and hope in the face of uncertainty.
However, Nome's journey is not without challenges. The company acknowledges that it is still in its early stages and that there is a long way to go before fully achieving its vision. Skeptics argue that adding an extra layer of cost to an already expensive process might not be sustainable. Yet, Ringel remains steadfast in his belief that Nome's services are essential for patient groups who desperately need support.
In conclusion, Nome represents a beacon of hope in the rare disease treatment landscape. By harnessing the power of AI and providing a comprehensive service, it is paving the way for more personalized and accessible treatments. As the startup continues to evolve and expand its reach, it has the potential to make a profound impact on the lives of countless patients and their families, offering a brighter future where rare diseases are no longer a daunting and isolating challenge.
